Annual report pursuant to Section 13 and 15(d)

Collaboration and Research Arrangements - Additional Information (Details)

v3.22.4
Collaboration and Research Arrangements - Additional Information (Details) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Dec. 17, 2019
Jan. 08, 2018
Nov. 30, 2022
Nov. 30, 2019
Jan. 31, 2018
Dec. 31, 2022
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Contract asset balances           $ 1,694,000 $ 1,694,000 $ 2,979,000  
Revenue recognized             $ 14,880,000 23,488,000 $ 15,093,000
Global Blood Therapeutics | Collaboration Agreement                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Initial period of research term 3 years                
Additional extension period for research term upon mutual agreement 1 year                
Additional extension period for research term     1 year       1 year    
Research agreement expiration month and year     2023-12            
Upfront payment receivable $ 20,000,000.0                
Reimbursements receivable of full-time employee and out-of-pocket costs and expenses $ 40,000,000.0                
Agreement termination, prior written notice if notice delivered during the research term 9 months                
Agreement termination, prior written notice if notice delivered after the expiration or termination of the research term 90 days                
Total transaction price $ 60,000,000.0           $ 49,200,000    
Research agreement additional consideration             7,100,000    
Upfront non-refundable and non-creditable payment 20,000,000.0                
Reimbursable costs $ 40,000,000.0                
Estimated transaction price           56,400,000 56,400,000    
Accounts receivable           0 0 0  
Contract asset balances           1,700,000 1,700,000 3,000,000.0  
Revenue recognized             13,600,000 19,400,000 11,700,000
Deferred revenue, short-term           4,300,000 4,300,000 9,000,000.0  
Decrease in revenue           800,000      
Global Blood Therapeutics | Collaboration Agreement | Maximum                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Period of extension of initial research term 2 years                
Receivable from option exercise, development, regulatory, commercialization and sales-based milestones per product candidate and product resulting $ 315,000,000.0                
Incyte                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Revenue recognized             1,300,000 $ 4,100,000 $ 3,400,000
Deferred revenue, short-term           $ 0 $ 0    
Incyte | Stock Purchase Agreement                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Aggregate purchase price         $ 10,000,000.0        
Shares issued         79,302        
Share price (in dollars per share)         $ 126.10        
Premium to volume-weighted sale price of shares (as a percent)         30.00%        
Trading days within which the purchase price represents a thirty percent (30%) premium to the volume-weighted sale price of the shares         15 days        
Incyte | Collaboration Agreement                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Total transaction price   $ 12,300,000   $ 12,800,000          
Upfront non-refundable and non-creditable payment       2,500,000          
Up-front consideration         $ 10,000,000.0        
Up-front consideration, cash         2,500,000        
Up-front consideration, pre-paid research funding         $ 7,500,000        
Prepaid research amount       7,500,000          
Premium paid on equity investment       2,300,000          
Collaboration agreement additional consideration incurred       $ 500,000